InvestorsHub Logo
Followers 134
Posts 22407
Boards Moderated 0
Alias Born 06/13/2011

Re: JRoon71 post# 428787

Monday, 09/09/2024 4:21:45 PM

Monday, September 09, 2024 4:21:45 PM

Post# of 437435
A friend ( secondary prevention now with 1 stent ) who I thought was a candidate for Vascepa ... was prescribed Jardiance instead .
His Cardiologist thought Jardiance treated a wider range of his risk factors ...which includes high blood pressure ...than Vascepa .
May be a trend


Jardiance has shown strong growth, with sales increasing by 30% in Q4 2023 compared to Q4 2022, and by 19% in Q1 2024 compared to Q1 2023. This growth is attributed to increased demand and expanded indications for the drug, including its use in treating heart failure and chronic kidney disease.



Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News